Dublin, Aug. 16, 2017 -- The "Antibody Target, Technology & Pipeline Database: 1-Year Subscription" newsletter has been added to Research and Markets' offering.
Subscription to this proprietary Antibody Database provides online access to information about more than 3,400 project entries for therapeutic antibodies on the market and in research & development.
Pre-established and free search functions allow to identify antibodies according to their:
- Technology (e.g. bispecifics, T-cell redirecting antibodies, antibody-drug conjugate, Fc-engineering, antibody format)
- Target (e.g. VEGF, immuen checkpoint modulators)
- Pipelines (selected by target, therapeutic area, company, technology)
- Sales (for marketed antibodies)
- R&D Phase (clinical phases, market, preclinical)
- Territory (countrywise)
- Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
- Drug Code/Name (for individual molecules)
Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic antibodies is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed.
Sales figures of major therapeutic antibodies on the market are provided. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:
- T-cell Redirecting Antibodies
- Immune Checkpoint Modulating Antibodies
- Antibody-Drug Conjugates
- Bispecific Antibodies
- Oligo- and Polyclonal Antibodies
- Biosimilar Antibodies
Benefits from the Antibody Pipeline Database:
- Intuitive use
- Continuously updated (input from e.g. press releases, scientific meetings, company presentations)
- Designed for structured searches
- Focused on targets, technologies, therapeutic areas and R&D phases
- Ideal for competitor analysis (companies, targets, technologies, R&D phase)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing candidates
Project listing in a tabular format:
- Drug Codes
- Target
- Class of Compound
- Company
- Territory
- Therapeutic Area
- Indication
- R&D Phase
Therapeutic Areas:
- Cardiovascular & blood
- Dermatology
- Gastrointestinal
- Genitourinary, renal & gynecology
- Infectious & toxicology
- Metabolism & endocrine
- Neurology & psychiatry
- Oncology
- Ophthalmology & otorhinolaryngology
- Orthopedics, dental, anesthesia & surgery
- Pulmonary & respiratory
- Rheumatoid & autoimmune
Predefined Technologies of the Scroll-Down Menu - examples:
- T-Cell Redirecting Antibodies
- Antibody-Drug Conjugates per Payload (e.g. Auristatin, PBD)
- Bispecific Antibodies
- Oligo- and Polyclonal Antibodies
- In vitro generated Antibodies (phage display)
- Fab Antibodies
- Fc-Fusion Proteins
- Agonist Antibodies
- Transgenic Mouse Antibodies (e.g. XenoMouse, VelocImmune Mouse, KM Mouse)
- Human Cell-Derived Antibodies
Predefined Targets of the Scroll Down Menu - examples:
- Amyloid & Tau
- Antibody Sales in 2015
- Biosimilar Antibodies
- BCMA
- CD19
- CD20
- CD22
- CD30
- CD33
- CD37
- CD38
- CD40/-L
- CD123
- CEA
- CGRP
- EGF-R
- EpCAM
- FGF/-R
- GM-CSF
- Her2
- Interleukin-1/R
- Interleukin-6/R
- Interleukin-23 & 12/23
- Interleukin-4/-13
- Interleukin-17
- LAG-3
- Mesothelin
- OX40/-L
- PCSK9
- PSMA
- TIM-3
- TNF
For more information about this newsletter visit https://www.researchandmarkets.com/research/w3c2hq/antibody_target
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biotechnology


SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile
Instagram Outage Disrupts Thousands of U.S. Users
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 



